White Paper
Clinical Trial ResearchWhat are Clinical Trials and Why is this Industry Booming?
Table of Contents
The US clinical trials industry represents a dynamic and pivotal component of the nation’s healthcare landscape, embodying the relentless pursuit of scientific advancement and medical innovation. At its core, clinical trials serve as the vanguard of medical research, orchestrating meticulously designed studies that evaluate the safety, efficacy, and benefits of new medical interventions across diverse patient populations.
2
A Catalyst for Medical Progress
Clinical trials, rather than just being scientific exercises, are complex processes that link scientific discovery to actual patient outcomes. They represent cooperative efforts between pharmaceutical and biotechnology firms, academic institutions, research outfits, care providers, regulatory agencies, and most importantly patients themselves. By adhering strictly to ethical standards, these hypotheses validate therapeutic concepts aiding in designing new therapies.
3
Empowering Precision Medicine and Personalized Care
In today’s era of fast growing personalized medicine, clinical trials are essential in adapting therapeutic decisions to the genetic, molecular, and clinical profiles of individual patients. Such a method not only improves the effectiveness of treatment but also reduces side effects. It allows for unique medical conditions through customized care pathways that capture every aspect of their complexity. The future of clinical trials is influenced by advances in genomics, biomarker identification, and data-driven insights.
4
Collaborative Ecosystem and Outsourcing Trends
The clinical trial ecosystem thrives on collaboration with stakeholders fostering synergies to drive innovation and scientific excellence. A notable trend in recent years is the outsourcing of activities to specialized service providers, including Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), and Site Management Organizations (SMOs). This strategic outsourcing model not only optimizes costs but also enables access to niche expertise, accelerates trial timelines, and ensures compliance with regulatory standards.
1. https://www.clinicaltrials.astellas.com/why-is-clinical-research-important/
2. https://medicover-mics.com/what-are-clinical-trials/
3.https://www.researchgate.net/publication/379822664_Evolving_role_of_clinical_laboratories_in_precision_medicine_a_narrative_review
4.https://www.appliedclinicaltrialsonline.com/view/outsourcing-model-usage-and-its-relationship-to-clinical-trial-performance
5. IBIS World – Industry Stats
Market Overview
The US clinical trials market is experiencing stable growth. It was valued at US$ 25.8 billion in 2023 and is projected to surpass US$ 41.6 billion by 2033, with a CAGR of 4.9%. This growth is driven by increasing investments in healthcare R&D, the growing prevalence of chronic diseases, and rising demand for innovative treatments. While pharmaceutical companies have traditionally conducted research, most funding now flows to non-institutional players or new entrants. On average, approximately 64% of clinical development services are outsourced.
U.S. Clinical Trials Market
Phase I
Phase II
Testing in a larger group of patients to evaluate effectiveness and side effects.
Phase III
Large-scale testing in a diverse patient population to confirm effectiveness, monitor side effects, and compare the new intervention with existing treatments.
Phase IV
Ongoing monitoring of the intervention after it has been approved and is available to the public.
1. https://www.novaoneadvisor.com/report/us -clinical-trials-market
2. Ibid.
3. Ibid.
4.https://www.gminsights.com/industry-analysis/clinical-trials-market
5.https://www.biospace.com/article/releases/clinical -trials-market-is-rising-rapidly-up-to-usd-95-bn-by-2030/
What’s driving the growth?
Advancements in Targeted Therapeutics through Healthcare Technology 1
The rapid advancements in healthcare technology, including digital health solutions, AI, data analytics, and telemedicine, are revolutionizing the clinical trials landscape in the US. Cutting-edge innovations such as gene and cell therapy and CRISPR are enabling researchers to develop targeted treatments for increasingly specific diseases. These technologies streamline trial processes, enhance data collection and analysis, improve patient engagement, and enable real-time monitoring. This technological prowess drives operational efficiencies, reduces costs, accelerates trial timelines, and enhances overall trial outcomes, significantly contributing to the growth of the clinical trials market.
Increasing R&D Investments 2
The US continues to lead in research and development (R&D) spending, with significant investments from pharmaceutical companies, biotechnology firms, academic institutions, and government agencies. The robust R&D ecosystem fosters innovation, drives scientific discovery, and fuels the development of novel therapies and treatments. These investments support a diverse pipeline of clinical trials across therapeutic areas, contributing to the growth and expansion of the clinical trials.
Increasing Demand for Personalized Medicine 3
The shift toward personalized medicine, tailored to individual patient characteristics, genomics, and biomarkers, is a significant driver shaping the clinical trials industry in the US. Precision medicine approaches require extensive clinical research, biomarker validation, and targeted therapies, driving the demand for specialized clinical trials.
Growing Prevalence of Chronic Diseases 4
The rising prevalence of chronic diseases, such as cardiovascular disorders, cancer, diabetes, and neurological conditions, presents a compelling need for innovative therapies and treatment modalities. Clinical trials targeting chronic diseases are at the forefront of research priorities, driving substantial investments, collaborations, and partnerships in the US. The imperative to address unmet medical needs, improve patient outcomes, and mitigate disease burden fuels the expansion of clinical trials in chronic disease management.
Growing Outsourcing of Clinical Trial Services 5
Pharmaceutical companies are increasingly outsourcing their clinical trial activities to specialized service providers, including CROs, CDMOs, and SMOs. Outsourcing allows companies to access expertise, reduce costs, and accelerate trial timelines, driving the clinical trial outsourcing market.
Increased Patient Engagement and Inclusion 6
Efforts to enhance patient engagement and inclusion in clinical trials are gaining momentum, driven by initiatives to improve diversity, equity, and accessibility in research. Patient-centric approaches, such as virtual trials, decentralized trials, and patient advocacy groups, are helping to overcome barriers to participation and accelerate recruitment, fostering growth in the industry.
1. https://www.precedenceresearch.com/clinical -trials-market
2. https://www.marketsandmarkets.com/Market -Reports/clinical-trials-market-405.html
3. Ibid.
4. Ibid.
5. https://www.biospace.com/article/releases/pharmaceutical -cdmo-industry-is-rising-rapidly-up-to-usd-295-95-bn-by-2033/
6. https://acrpnet.org/2024/01/enhancement -efficiency-equity-and-engagement-four-trends-shaping-clinical-trials-in-2024/
M&A Landscape
The clinical trial research landscape has witnessed significant transformation in recent years. Since COVID-19, the market saw a surge in mergers and acquisitions (M&A) activity in 2021, which has since slowed down somewhat. The following analysis delves into the key trends and dynamics shaping the M&A landscape within the clinical trial research sector, particularly focusing on the US.
Fragmentation and Consolidation 1
The clinical research site market, historically fragmented, has experienced a notable shift toward consolidation. The emergence of approximately 30 private equity-backed site platforms, representing around 15% of the global market, highlights the growing trend of consolidation within this segment.
Impact of COVID-19 Pandemic 2
The COVID19 pandemic acted as a catalyst for rapid scaling and consolidation within the clinical trial research sector. The necessity to adapt to pandemic-related challenges, coupled with the imperative to accelerate drug development timelines, prompted increased M&A activity among large CROs.
Diverse M&A Strategies 3
M&A activities within the sector have showcased diverse strategic approaches, including acquisitions focused on specialized capabilities, geographic expansion, and technology driven solutions. For instance, acquisitions targeting firms with expertise in specific therapeutic areas, such as ophthalmology, dermatology, oncology, and medical devices, have been prevalent, reflecting the industry’s emphasis on tailored solutions and niche services.
Private Equity Interest 4
Private equity investors have shown considerable interest in the clinical trial research sector, viewing CROs and research sites as attractive assets with robust cash flow potential. The influx of private equity capital has fueled M&A transactions, enabled strategic expansions, and facilitated the development of innovative service offerings.
Sponsor Preferences and Challenges 5
Sponsors’ preferences in outsourcing clinical trials have evolved in response to M&A dynamics within the CRO sector. Concerns about large CRO instability, disruptions to project teams, and challenges in service delivery have led sponsors, particularly small and emerging companies, to reevaluate their partnerships. Midsize CROs have emerged as preferred partners, offering specialized services, personalized attention, and cost effective solutions.
1. https://www.precedenceresearch.com/clinical -trials-market
2. https://www.marketsandmarkets.com/Market -Reports/clinical-trials-market-405.html
3. Ibid.
4. Ibid.
5. https://www.biospace.com/article/releases/pharmaceutical -cdmo-industry-is-rising-rapidly-up-to-usd-295-95-bn-by-2033/
6. https://acrpnet.org/2024/01/enhancement -efficiency-equity-and-engagement-four-trends-shaping-clinical-trials-in-2024/
A Vision for the Future
Looking ahead, the landscape of clinical trial research is poised for significant transformation. The growing complexity of clinical trial designs is generating vast amounts of data from diverse sources. This trend is driven by the biopharmaceutical industry’s shift toward ambitious, customized drug development targeting rare diseases, and utilizing biomarker and genetic data to stratify participant subgroups.
Data-centric Approach to Drug Development 1
The future of pharmaceutical industry leadership is expected to shift toward data scientists and technology giants such as Google, Amazon, and Apple. The centrality of data in clinical trials will empower algorithms managed by data scientists to drive drug development processes, focusing on safety and efficacy assessments through advanced analytics and AI-driven insights. Mergers and partnerships between traditional pharmaceutical companies and tech giants reflect the growing acceptance of data-driven end-toend solutions in drug development and reimbursement pathways.
Impact of Wearables and Diagnostics 2
Wearable technologies and implantable biosensors are poised to become commonplace by 2050, revolutionizing patient monitoring and drug delivery. Responsive drug delivery systems will enable personalized treatment regimens, optimizing medication administration based on realtime patient data. This shift toward personalized medicine and data-driven dosing strategies will not only enhance patient outcomes but also streamline clinical trial recruitment and participant identification.
Role of Artificial Intelligence in Clinical Trials3
Artificial intelligence (AI) will play a pivotal role in optimizing clinical trial processes, from study design to participant recruitment and data analysis. AI algorithms will leverage historical data and real-time insights to optimize study protocols, identify disease-specific centers of excellence, and streamline patient identification for trials. Simulation-guided by AI will enable preclinical characterization of therapies, optimal dosing strategies, and large-scale population modeling, revolutionizing trial efficiency and cost-effectiveness.
Transformation of Registration and Reimbursement4
The registration process for new therapies is expected to evolve toward real-time coordination and adaptive trial designs. Regulatory authorities will leverage integrated data management systems and AI-powered analytics to monitor trials in real time, reducing administrative burdens and accelerating drug approval timelines. Reimbursement models will likely shift toward outcomes-based pricing, linking payment to treatment efficacy and patient outcomes, fostering a more efficient and value-driven approach to healthcare delivery.
Future of Disease Understanding and Treatment Paradigms5
Advancements in technology will deepen our understanding of diseases, leading to personalized treatments tailored to individual needs. Smart medicines, gene profiling, and responsive drug delivery will define the era of precision medicine while testing in diverse patient populations will ensure broader applicability of treatments.
MAXIMIZED VALUE
As skilled negotiators, investment bankers can help physicians get the best possible price for their practice and structure the deal in a way that minimizes tax liabilities and maximizes the financial benefits for the sellers. Investment bankers build a financial model that ensures proper treatment of normalizing adjustments and the quantification of growth opportunities, providing a robust financial picture for potential buyers.
Additionally, a strong multiple isn’t enough. Healthcare transactions are considered a hybrid with trailing earnings, a historical and a steady state component, and forward earnings, a projected growth component. When both types of earnings are prepared and presented in a credible manner, the overall valuation will be increased. Investment bankers understand how to dig into the numbers and best position the practice for optimal outcomes.
POSITIONED FOR A HIGHER VALUATION: TRAILING AND FORWARD EARNINGS
With a trailing multiple of 14x and a forward multiple of 10x, the overall valuation is $70,000,000
CREDIBILITY
Representation by an investment banking partner lends credibility to the transaction and prevents lowball offers. Potential buyers understand there’s a competitive process at play and the seller is committed to seeing the deal through.
ACCESS TO A LARGE NETWORK OF BUYERS
With a broad network of contacts, including private equity firms, strategic buyers, and other investors, investment bankers can quickly identify potential buyers. The large network also encourages a competitive bidding process and drives a higher valuation, allowing sellers to feel confident that they received the right price and financial and non-financial terms.
CONFIDENTIALITY
Maintaining confidentiality among physicians, board of directors, attorneys, accountants, and other stakeholders is critical to any M&A transaction. If sensitive information such as reimbursement rates are leaked, the valuation could be affected. Physician owners may also not want their patients, staff, and competitors to know about their plans. By facilitating non-disclosure agreements (NDAs) and screening potential buyers, investment bankers ensure the strictest level of confidentiality is maintained.
A FASTER AND SMOOTHER PROCESS
Challenges are bound to arise, but working with an experienced investment banking partner can ensure issues are resolved, deadlines are adhered to, and the process moves forward without pulling sellers away from running their businesses. Investment bankers can also help sellers navigate challenges that come up after letters of intent (LOI) are executed before the close. These may include unexpected physician departures and financial, legal, or regulatory issues that were unearthed during the due diligence process.
CONTROL AND GOVERNANCE
A good investment banker will help owners focus on areas of value to them outside of the purchase price and can advise on what to expect and how to best negotiate post-deal governance rights. Different buyers (hospital systems and strategic buyers vs. private equity platform buyers) might offer different levels of autonomy. An investment banker can help owners prioritize their goals and flush out with buyers decisions around the business of the practice and patient care well before a deal closes.
1. https://www.capgemini.com/wp-content/uploads/2022/01/The-Clinical-Trial-of-the-Future-2021.pdf
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259497/
3. Ibid.
4. Ibid.
5. Ibid.
Conclusion
The landscape of clinical trial research in the US, and globally, is not just transforming; it is experiencing a revolution fueled by data, technology, collaboration, and a relentless pursuit of improving human health. As we delve into the complexities and opportunities of this dynamic industry, several key insights emerge that illuminate the path forward for clinical trials and healthcare innovation.
One of the most striking aspects of the clinical trial research industry is its adaptability and resilience in the face of challenges. From navigating regulatory complexities to overcoming patient recruitment hurdles, the industry has consistently demonstrated a capacity for innovation and problem-solving. This adaptability will continue to be a driving force as the industry embraces new technologies, methodologies, and collaborative models.
Speaking of collaboration, the future of clinical trials lies in interdisciplinary partnerships that leverage the strengths of diverse stakeholders. Collaborations between pharmaceutical companies, tech giants, academic institutions, healthcare providers, and patient advocacy groups are fostering a holistic approach to clinical research. These partnerships enhance the quality and efficiency of trials and ensure that patient voices are central to the process, leading to more meaningful outcomes.
Data and technology are undoubtedly the cornerstones of the future clinical trial landscape. The integration of wearables, AIdriven analytics, real-time monitoring systems, and personalized medicine approaches is revolutionizing how trials are conducted, monitored, and analyzed. This data-centric approach optimizes trial processes and enables more accurate assessments of treatment efficacy, safety, and patient outcomes.
Looking ahead, the industry must continue to prioritize inclusivity, diversity, and patient centricity. Efforts to enhance patient engagement, improve accessibility to trials, and address disparities in healthcare access will be crucial in ensuring that clinical research benefits all segments of society equitably.
In essence, the booming global clinical trials industry represents a beacon of hope and progress in healthcare. It embodies the collaborative spirit of innovation, the transformative power of data and technology, and the unwavering commitment to improving human lives. As we navigate the complexities and opportunities of the future, let us forge ahead with a shared vision of advancing medical science, enhancing patient outcomes, and shaping a healthier, more resilient world for future generations.
About Merritt Healthcare Advisors
Merritt Healthcare Advisors (“MHA”) is focused exclusively on representing owners of middle-market healthcare businesses that are considering strategic options, whether it is selling an interest in their organization, creating a new partnership, or growing through acquisition. MHA is unique in that we are the only firm that combines an investment banking background with actual “owners” experience that comes from developing and managing our own healthcare facilities. We have used this experience to successfully complete more than $5 billion in transactions on behalf of our Clients. As the industry’s leading Mergers and Acquisitions (“M&A”) firm, our proven process and extensive buyer network enable us to help our Clients realize the absolute best financial and non-financial outcomes. The Principals of Merritt acted in their capacity of licensed investment banking agents of Burch & Company, Inc., member FINRA/SIPC. For additional information about Merritt Healthcare Advisors, please visit www. merrittadvisory.com
Contact Us
Contact Merritt
John Carron – Partner
jcarron@merrittadvisory.com
(917) 647-8218
Zak Eisenberg – Vice President
zeisenberg@merrittadvisory.com
(914) 815-5479
Connecticut Office
63 Copps Hill, 22A Ridgefield,
CT 06877
(914) 556-6266
West Coast Office
521 Bachman Ave
Los Gatos, CA 95030
merrittadvisory.com
*Registered Investment Banking Agent with Series 79 and 63 licenses. Securities offered through Burch & Company, Inc. Merritt Healthcare and Burch & Company, Inc. (4151 N. Mulberry Drive, Suite 235, Kansas City, MO 64116) are not affiliated entities.
